Evidence map›Paper›PMID 36049504›Full record

ArticleNature2022

Screening for generality in asymmetric catalysis.

Corin C Wagen, Spencer E McMinn, Eugene E Kwan, Eric N Jacobsen

Open access · greenAbstract read
In one paragraph

Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 113 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Promiscuity-Guided Enzyme Evolution via Substrate Multiplexed Screening.Angewandte Chemie (International ed. in English) · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Desymmetrization ofJournal of the American Chemical Society · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Corin C Wagen *Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-3315-3524
Spencer E McMinn *Discovery Chemistry, Merck & Co. Inc, Boston, MA, USA.
Eugene E KwanProcess Research and Development, Merck & Co. Inc, Boston, MA, USA. eugene.kwan@merck.com.ORCID http://orcid.org/0000-0001-7037-0531
Eric N JacobsenDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA. jacobsen@chemistry.harvard.edu.ORCID http://orcid.org/0000-0001-7952-3661
Harvard University · USMerck & Co., Inc., Rahway, NJ, USA (United States) · US

Funding

CHIRAL COMPLEXES DESIGNED TO CATALYZE ORGANIC REACTIONSR01GM043214 · NIGMS · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI JACOBSEN, ERIC N · 1991 to 2023
$9.4M
Chiral Catalysts Designed to Catalyze Organic ReactionsR37GM043214 · NIGMS · HARVARD UNIVERSITY · PI JACOBSEN, ERIC N · 2002 to 2011
$6.6M
NIGMS NIH HHS R01 GM043214NIGMS NIH HHS R37 GM043214
6 · The paper itself

Abstract

Research in the field of asymmetric catalysis over the past half century has resulted in landmark advances, enabling the efficient synthesis of chiral building blocks, pharmaceuticals and natural products

Indexed as

Biological ProductsChemistry Techniques, SyntheticPharmaceutical PreparationsCatalysisChromatography, Supercritical FluidMass SpectrometryStereoisomerismSubstrate SpecificityBiological ProductsPharmaceutical Preparations

Identifiers

PMID36049504
PMCPMC9645431
OpenAlexW4294051898

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.